The RIO study is looking at whether a new type of treatment can keep viral load undetectable without ART. This will involve asking all participants to stop ART for a short time.
The study will measure how long viral load stays undetectable without ART. It will also look at what happens to the HIV virus and immune system in blood samples. When virus becomes detectable in a blood test (viral rebound) you will be asked to re-start your ART.
- RIO trial opens for recruitmentThe RIO clinical trial will test whether a new type of therapy can keep HIV under control without daily antiretroviral […]
- RIO trial protocol preprint available on Research SquareRead about our #RIOtrial protocol, and the benefits of early and integrated community involvement during study design. […]
- Integration features of intact latent HIV-1 in CD4+ T cell clones contribute to viral persistence
- PopART-IBM, a highly efficient stochastic individual-based simulation model of generalised HIV epidemics developed in the context of the HPTN 071 (PopART) trial
- Motivating people living with HIV to initiate antiretroviral treatment outside national guidelines in three clinics in the HPTN 071 (PopART) trial, South Africa
- Heightened resistance to host type 1 interferons characterizes HIV-1 at transmission and after antiretroviral therapy interruption
- Sequence Evaluation and Comparative Analysis of Novel Assays for Intact Proviral HIV-1 DNA
RIO is funded by the Bill & Melinda Gates Foundation. Imperial College London is the Trial Sponsor and the trial is coordinated by Imperial College London, The University of Oxford and The Rockefeller University.